If you've been researching treatments for depression, you've likely come across both Spravato (esketamine) and IV ketamine. While these treatments share a common pharmacological foundation, they differ significantly in ways that matter to patients.
The Connection
Both Spravato and ketamine act on the brain's glutamate system — specifically, NMDA receptors. This is fundamentally different from traditional antidepressants, which target serotonin, norepinephrine, or dopamine pathways. By working through a different mechanism, these treatments can help patients who haven't responded to conventional medications.
Spravato (esketamine) is the S-enantiomer of ketamine — essentially, one half of the ketamine molecule, isolated and refined for clinical use.
Key Differences
FDA Approval
Spravato is FDA-approved for two specific indications: treatment-resistant depression (TRD) and major depressive disorder with acute suicidal ideation or behavior. It has undergone rigorous Phase III clinical trials.
IV Ketamine for depression is considered off-label use. While ketamine is FDA-approved as an anesthetic, its use for depression has not gone through the formal FDA approval process.
Administration
Spravato is a self-administered nasal spray, taken under clinical supervision. The process is standardized and consistent across certified treatment centers.
IV Ketamine is delivered through an intravenous infusion, typically over 40 minutes. Dosing protocols can vary between clinics.
Insurance Coverage
Spravato, as an FDA-approved treatment, is covered by most major insurance plans, including Medicare. Prior authorization is required but typically attainable for qualifying patients.
IV Ketamine is generally not covered by insurance for depression treatment due to its off-label status. Patients typically pay out-of-pocket, with costs ranging from $400–$800 per infusion.
Safety Protocol
Spravato is administered under the FDA's REMS (Risk Evaluation and Mitigation Strategy) program, which mandates certified treatment settings, 2-hour post-dose monitoring, and strict documentation requirements.
IV Ketamine clinics operate without a standardized federal safety framework. Quality and safety protocols vary by provider.
Which Is Right for You?
For most patients with treatment-resistant depression, Spravato offers significant advantages: FDA approval, insurance coverage, standardized safety protocols, and a well-defined treatment pathway. At Restore Brain, we offer Spravato as part of our comprehensive approach to treatment-resistant depression.
Contact our team to discuss which treatment option may be best for your situation.
Ready to Explore Your Options?
Schedule a free, no-obligation consultation with our clinical team.